Acid sphingomyelinase is required for cell surface presentation of Met receptor tyrosine kinase in cancer cells

被引:19
|
作者
Zhu, Linyu [1 ,2 ]
Xiong, Xiahui [2 ]
Kim, Yongsoon [2 ]
Okada, Naomi [2 ]
Lu, Fei [1 ]
Zhang, Hui [2 ]
Sun, Hong [2 ]
机构
[1] Peking Univ, Shenzhen Grad Sch, Sch Chem Biol & Biotechnol, Shenzhen 518055, Guangdong, Peoples R China
[2] Univ Nevada, Dept Chem & Biochem, Las Vegas, NV 89135 USA
基金
美国国家卫生研究院; 中国国家自然科学基金;
关键词
Acid Sphingomyelinase; ASM; Syntaxin; 6; STX6; Met; Ceramide; Golgi; SMPD1; Receptor tyrosine kinase; RTK; ORGANELLE STRUCTURE; EARLY ENDOSOMES; LIVING CELLS; LIPID RAFTS; GOLGI; RESISTANCE; LYSOSOMES; TRANSPORT; CERAMIDE; DEGRADATION;
D O I
10.1242/jcs.191684
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Receptor tyrosine kinases (RTKs) are embedded in the lipid bilayer of the plasma membrane, but the specific roles of various lipids in cell signaling remain largely uncharacterized. We have previously found that acid sphingomyelinase (ASM; also known as SMPD1) regulates the conserved DAF-2 (the ortholog IGF-1R in mammals) RTK signaling pathway in Caenorhabditis elegans. How ASM and its catalytic products, ceramides, control RTK signaling pathways remain unclear. Here, we report that ASM regulates the homeostasis of Met, an RTK that is frequently overexpressed in various cancers. Inactivation of ASM led to a rapid loss of Met from the plasma membrane, reduced Met phosphorylation and activation, and induced Met accumulation in the trans-Golgi network (TGN). However, trafficking of integrin beta 3 and vesicular stomatitis virus glycoprotein (VSVG) was largely unaffected. Knockdown of syntaxin 6 (STX6) also blocked the Golgi exit of Met. Depletion of either ASM or STX6 led to aberrant trafficking of Met to lysosomes, promoting its degradation. Our studies reveal that ASM and ceramides, together with STX6 and cholesterol, constitute a new regulatory mechanism for the exit of Met from the Golgi during its biosynthetic route, which is used to rapidly replenish and regulate the plasma membrane levels of Met in various cancer cells.
引用
收藏
页码:4238 / 4251
页数:14
相关论文
共 50 条
  • [21] The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance
    Miekus, Katarzyna
    ONCOLOGY REPORTS, 2017, 37 (02) : 647 - 656
  • [22] Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
    Agwa, Eberechi S.
    Ma, Patrick C.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 397 - 404
  • [23] The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer
    Sattler, Martin
    Salgia, Ravi
    CELL REPORTS MEDICINE, 2025, 6 (03)
  • [24] Genetic targeting of the kinase activity of the Met receptor in cancer cells
    Arena, Sabrina
    Pisacane, Alberto
    Mazzone, Massimiliano
    Comoglio, Paolo Maria
    Bardelli, Alberto
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (27) : 11412 - 11417
  • [25] MET TYROSINE KINASE RECEPTOR EXPRESSION IN PITUITARY ADENOMAS
    Kim, S.
    Lee, B.
    Kim, H.
    Lee, J.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1134 - 1134
  • [26] MET receptor tyrosine kinase as a therapeutic anticancer target
    Stellrecht, Christine M.
    Gandhi, Varsha
    CANCER LETTERS, 2009, 280 (01) : 1 - 14
  • [27] AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity
    Schmid, Edward T.
    Pang, Iris K.
    Silva, Eugenio A. Carrera
    Bosurgi, Lidia
    Miner, Jonathan J.
    Diamond, Michael S.
    Iwasaki, Akiko
    Rothlin, Carla V.
    ELIFE, 2016, 5
  • [28] Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Yao, Yu
    Yang, Huaping
    Zhu, Bo
    Wang, Song
    Pang, Jiaohui
    Wu, Xiaoying
    Xu, Yang
    Zhang, Junli
    Zhang, Jinfeng
    Ou, Qiuxiang
    Tian, Hui
    Zhao, Zheng
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [29] Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Yu Yao
    Huaping Yang
    Bo Zhu
    Song Wang
    Jiaohui Pang
    Xiaoying Wu
    Yang Xu
    Junli Zhang
    Jinfeng Zhang
    Qiuxiang Ou
    Hui Tian
    Zheng Zhao
    Respiratory Research, 24
  • [30] Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase
    Orlando, Eleonora
    Aebersold, Daniel Matthias
    Medova, Michaela
    Zimmer, Yitzhak
    CANCER LETTERS, 2019, 443 : 189 - 202